The Impact of Anti-TNF Exposure on Vedolizumab Effectiveness
Vedolizumab is a new medication being used for the treatment of Crohn's disease and Ulcerative colitis. It works by blocking specific white blood cells (alpha 4-beta7 lymphocytes) from migrating to areas of inflammation in the gastrointestinal tract. Previous studies have shown that patients who have previous exposure to another type of medication for Crohn's disease and Ulcerative colitis (anti-TNF medications) do not respond to vedolizumab as well as those who have never been exposed. This study will investigate biologic markers in the blood and tissue the help identify possible reasons for this difference.
Study Type: Observational
Actual Enrollment: 50 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Impact of Anti-TNF Exposure on Vedolizumab Effectiveness: A Biomarker Study.
Study Start Date: June 2015
Primary Completion Date: June 13, 2017
Study Completion Date: June 13, 2017
Groups and Cohorts:
- Anti-TNF Exposure
- anti-TNF Naive
| Category | Value |
|---|---|
| Date last updated at source | 2017-09-13 |
| Study type(s) | Observational study |
| Expected enrolment | 50 |
| Study start date | 2015-06-01 |
| Estimated primary completion date | 2017-06-13 |